Dose-dependent reduced haloperidol/haloperidol ratios

Influence of patient-related variables

Hsien Yuan Lane, Wen Ho Chang, Yue Cune Chang, Oliver Yoa Pu Hu, Hsin Nan Lin, Michael W. Jann, Wei Herng Hu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Plasma reduced haloperidol (RH) concentrations or RH to haloperidol (HL) ratios have been suggested to be important in determining the clinical efficacy and extrapyramidal side effects of HL. In this study, we measured the steady-state plasma HL and RH levels by high performance liquid chromatography and analyzed the effects of various variables (dose, gender, age, and body weight) on RH/HL ratios in four dose groups of Chinese schizophrenic inpatients: 10 mg/day (n = 84), 20 (n = 111), 30 (n = 29), and 60 (n = 55). In addition, the polymorphic distribution of RH/HL ratios, suggested by previous investigators, was further tested in each dosage group (for controlling the potential dosage effect on RH/HL ratios). As a result, both age and body weight could influence RH/HL ratios. Each year increase in age (after adjusting the effects of gender, body weight, and dosage) would elevate the RH/HL ratio by 0.0067 (P < 0.0001). On the other hand, after adjusting gender, age, and dosage effects, each kg increment in body weight would decrease the RH/HL ratio by 0.0044 (P < 0.01). Gender did not influence the ratio. Furthermore, the high dosage groups had higher RH/HL ratios (even with other variables being controlled). In comparison with the 10 mg group, the 60 mg group exhibited a higher mean RH/HL ratio by 0.84 (P < 0.0001) and the 30 mg group did by 0.31 (P < 0.0001). The 20 mg group was almost equal to the 10 mg group in RH/HL ratios. Besides, at each dosage group, the frequency distribution of RH/HL ratios seemed to be predominantly unimodal with a small proportion of extreme outliers. The results of this study clearly indicate that aging or high dose (≤ 30 mg/day) of HL could raise the plasma RH/HL ratio, while an increasing body weight would reduce that. In contrast, gender does not affect the ratios.

Original languageEnglish
Pages (from-to)127-132
Number of pages6
JournalPsychiatry Research
Volume72
Issue number2
DOIs
Publication statusPublished - Sep 19 1997
Externally publishedYes

Fingerprint

Haloperidol
Body Weight
4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol
Inpatients

Keywords

  • Age
  • Chinese
  • Dosage
  • Plasma levels

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Lane, H. Y., Chang, W. H., Chang, Y. C., Hu, O. Y. P., Lin, H. N., Jann, M. W., & Hu, W. H. (1997). Dose-dependent reduced haloperidol/haloperidol ratios: Influence of patient-related variables. Psychiatry Research, 72(2), 127-132. https://doi.org/10.1016/S0165-1781(97)00078-4

Dose-dependent reduced haloperidol/haloperidol ratios : Influence of patient-related variables. / Lane, Hsien Yuan; Chang, Wen Ho; Chang, Yue Cune; Hu, Oliver Yoa Pu; Lin, Hsin Nan; Jann, Michael W.; Hu, Wei Herng.

In: Psychiatry Research, Vol. 72, No. 2, 19.09.1997, p. 127-132.

Research output: Contribution to journalArticle

Lane, HY, Chang, WH, Chang, YC, Hu, OYP, Lin, HN, Jann, MW & Hu, WH 1997, 'Dose-dependent reduced haloperidol/haloperidol ratios: Influence of patient-related variables', Psychiatry Research, vol. 72, no. 2, pp. 127-132. https://doi.org/10.1016/S0165-1781(97)00078-4
Lane, Hsien Yuan ; Chang, Wen Ho ; Chang, Yue Cune ; Hu, Oliver Yoa Pu ; Lin, Hsin Nan ; Jann, Michael W. ; Hu, Wei Herng. / Dose-dependent reduced haloperidol/haloperidol ratios : Influence of patient-related variables. In: Psychiatry Research. 1997 ; Vol. 72, No. 2. pp. 127-132.
@article{b7b813bf5bda49909d477d9647917b55,
title = "Dose-dependent reduced haloperidol/haloperidol ratios: Influence of patient-related variables",
abstract = "Plasma reduced haloperidol (RH) concentrations or RH to haloperidol (HL) ratios have been suggested to be important in determining the clinical efficacy and extrapyramidal side effects of HL. In this study, we measured the steady-state plasma HL and RH levels by high performance liquid chromatography and analyzed the effects of various variables (dose, gender, age, and body weight) on RH/HL ratios in four dose groups of Chinese schizophrenic inpatients: 10 mg/day (n = 84), 20 (n = 111), 30 (n = 29), and 60 (n = 55). In addition, the polymorphic distribution of RH/HL ratios, suggested by previous investigators, was further tested in each dosage group (for controlling the potential dosage effect on RH/HL ratios). As a result, both age and body weight could influence RH/HL ratios. Each year increase in age (after adjusting the effects of gender, body weight, and dosage) would elevate the RH/HL ratio by 0.0067 (P < 0.0001). On the other hand, after adjusting gender, age, and dosage effects, each kg increment in body weight would decrease the RH/HL ratio by 0.0044 (P < 0.01). Gender did not influence the ratio. Furthermore, the high dosage groups had higher RH/HL ratios (even with other variables being controlled). In comparison with the 10 mg group, the 60 mg group exhibited a higher mean RH/HL ratio by 0.84 (P < 0.0001) and the 30 mg group did by 0.31 (P < 0.0001). The 20 mg group was almost equal to the 10 mg group in RH/HL ratios. Besides, at each dosage group, the frequency distribution of RH/HL ratios seemed to be predominantly unimodal with a small proportion of extreme outliers. The results of this study clearly indicate that aging or high dose (≤ 30 mg/day) of HL could raise the plasma RH/HL ratio, while an increasing body weight would reduce that. In contrast, gender does not affect the ratios.",
keywords = "Age, Chinese, Dosage, Plasma levels",
author = "Lane, {Hsien Yuan} and Chang, {Wen Ho} and Chang, {Yue Cune} and Hu, {Oliver Yoa Pu} and Lin, {Hsin Nan} and Jann, {Michael W.} and Hu, {Wei Herng}",
year = "1997",
month = "9",
day = "19",
doi = "10.1016/S0165-1781(97)00078-4",
language = "English",
volume = "72",
pages = "127--132",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Dose-dependent reduced haloperidol/haloperidol ratios

T2 - Influence of patient-related variables

AU - Lane, Hsien Yuan

AU - Chang, Wen Ho

AU - Chang, Yue Cune

AU - Hu, Oliver Yoa Pu

AU - Lin, Hsin Nan

AU - Jann, Michael W.

AU - Hu, Wei Herng

PY - 1997/9/19

Y1 - 1997/9/19

N2 - Plasma reduced haloperidol (RH) concentrations or RH to haloperidol (HL) ratios have been suggested to be important in determining the clinical efficacy and extrapyramidal side effects of HL. In this study, we measured the steady-state plasma HL and RH levels by high performance liquid chromatography and analyzed the effects of various variables (dose, gender, age, and body weight) on RH/HL ratios in four dose groups of Chinese schizophrenic inpatients: 10 mg/day (n = 84), 20 (n = 111), 30 (n = 29), and 60 (n = 55). In addition, the polymorphic distribution of RH/HL ratios, suggested by previous investigators, was further tested in each dosage group (for controlling the potential dosage effect on RH/HL ratios). As a result, both age and body weight could influence RH/HL ratios. Each year increase in age (after adjusting the effects of gender, body weight, and dosage) would elevate the RH/HL ratio by 0.0067 (P < 0.0001). On the other hand, after adjusting gender, age, and dosage effects, each kg increment in body weight would decrease the RH/HL ratio by 0.0044 (P < 0.01). Gender did not influence the ratio. Furthermore, the high dosage groups had higher RH/HL ratios (even with other variables being controlled). In comparison with the 10 mg group, the 60 mg group exhibited a higher mean RH/HL ratio by 0.84 (P < 0.0001) and the 30 mg group did by 0.31 (P < 0.0001). The 20 mg group was almost equal to the 10 mg group in RH/HL ratios. Besides, at each dosage group, the frequency distribution of RH/HL ratios seemed to be predominantly unimodal with a small proportion of extreme outliers. The results of this study clearly indicate that aging or high dose (≤ 30 mg/day) of HL could raise the plasma RH/HL ratio, while an increasing body weight would reduce that. In contrast, gender does not affect the ratios.

AB - Plasma reduced haloperidol (RH) concentrations or RH to haloperidol (HL) ratios have been suggested to be important in determining the clinical efficacy and extrapyramidal side effects of HL. In this study, we measured the steady-state plasma HL and RH levels by high performance liquid chromatography and analyzed the effects of various variables (dose, gender, age, and body weight) on RH/HL ratios in four dose groups of Chinese schizophrenic inpatients: 10 mg/day (n = 84), 20 (n = 111), 30 (n = 29), and 60 (n = 55). In addition, the polymorphic distribution of RH/HL ratios, suggested by previous investigators, was further tested in each dosage group (for controlling the potential dosage effect on RH/HL ratios). As a result, both age and body weight could influence RH/HL ratios. Each year increase in age (after adjusting the effects of gender, body weight, and dosage) would elevate the RH/HL ratio by 0.0067 (P < 0.0001). On the other hand, after adjusting gender, age, and dosage effects, each kg increment in body weight would decrease the RH/HL ratio by 0.0044 (P < 0.01). Gender did not influence the ratio. Furthermore, the high dosage groups had higher RH/HL ratios (even with other variables being controlled). In comparison with the 10 mg group, the 60 mg group exhibited a higher mean RH/HL ratio by 0.84 (P < 0.0001) and the 30 mg group did by 0.31 (P < 0.0001). The 20 mg group was almost equal to the 10 mg group in RH/HL ratios. Besides, at each dosage group, the frequency distribution of RH/HL ratios seemed to be predominantly unimodal with a small proportion of extreme outliers. The results of this study clearly indicate that aging or high dose (≤ 30 mg/day) of HL could raise the plasma RH/HL ratio, while an increasing body weight would reduce that. In contrast, gender does not affect the ratios.

KW - Age

KW - Chinese

KW - Dosage

KW - Plasma levels

UR - http://www.scopus.com/inward/record.url?scp=0030801794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030801794&partnerID=8YFLogxK

U2 - 10.1016/S0165-1781(97)00078-4

DO - 10.1016/S0165-1781(97)00078-4

M3 - Article

VL - 72

SP - 127

EP - 132

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 2

ER -